Sarepta Therapeutics,, Inc. Common Stock (SRPT) News
Latest headlines that mention SRPT, newest first · each headline opens the original publisher
- Last price
- $17.80
- Day change
- -0.14%
- Next earnings
- —
SRPT headlines
latest coverageGene therapy demand stabilizes while siRNA readouts and FDA talks loom ahead.
Revenue fell 34% YoY as management narrows guidance and eyes 2027 growth.
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients. The post Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space appeared first on Investor's Business Daily .
Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys. The post Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy? appeared first on Investor's Business Daily .
SRPT news alerts
Get an alert by email or push when a new headline mentions SRPT.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.